Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN85,5485,551,69
Msft-0,22
Nokia4,4114,466-0,23
IBM-0,70
Mercedes-Benz Group AG50,7450,761,98
PFE1,51
09.07.2025 0:38:52
Indexy online
AD Index online
select
AD Index online
 

  • 08.07.2025 21:59:28
Hyperion DEFI Inc (NASDAQ Cons)
Poslední obchod Změna (%) Změna (USD) Objem obchodů (ks)
11,27 -0,97 -0,11 809 416
After-hours09.07.2025 0:37:14
Poslední obchod Nákup / Prodej Změna (%) Změna (USD)
11,75 - - 1,58 0,18
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 09.07.2025
Popis společnosti
Obecné informace
Název společnostiHyperion DeFi Inc
TickerHYPD
Kmenové akcie:Ordinary Shares
RICHYPD.O
ISIN-
Poslední známé roční výsledky31.12.2024
Poslední známé čtvrtletní výsledky31.03.2025
Počet zaměstnanců k 15.03.2025 13
Akcie v oběhu k 20.06.2025 5 104 355
MěnaUSD
Kontaktní informace
Ulice23461 SOUTH POINTE DRIVE,, SUITE 390
MěstoLAGUNA HILLS
PSČ92653
ZeměUnited States
Kontatní osobaEric Ribner
Funkce kontaktní osobyInvestor Relations
Telefon18 137 669 539
Fax13026365454
Kontatní telefon16 467 514 363

Business Summary: Hyperion DeFi, Inc. is engaged in building a long-term strategic treasury of Hyperliquid’s native token, HYPE. The Company is focused on providing simplified access to the Hyperliquid ecosystem. It is also developing its proprietary Optejet User Filled Device (UFD) that is designed to work with a variety of topical ophthalmic liquids, including artificial tears and lens rewetting products. The Optejet is useful in chronic front-of-the-eye diseases due to its ease of use, enhanced safety and tolerability, and potential for superior compliance versus standard eye drops. Together, these benefits may result in higher treatment compliance and better outcomes for patients and providers. It has launched its cryptocurrency treasury reserve, which is native to the decentralized digital asset exchange and Layer-1 blockchain, Hyperliquid. Hyperliquid is a layer one blockchain (L1) written and optimized from first principles.
Financial Summary: BRIEF: For the three months ended 31 March 2025, Eyenovia Inc revenues increased from $5K to $15K. Net loss decreased 68% to $3.5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Research and development - Balancing val decrease of 90% to $188K (expense), Labor & Related Expenses in R&D decrease of 79% to $420K (expense).
Odvětvová klasifikace
TRBC2012Pharmaceuticals (NEC)
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSPharmaceutical Preparation Manufacturing
NAICSResearch and Development in Biotechnology (except Nanobiotechnology)
NAICS2007Pharmaceutical Preparation Mfg
NAICS1997Pharmaceutical Preparation Manufacturing
SICPharmaceutical Preparations
SICCommercial Physical Research



  • Poslední aktualizace: 09.07.2025
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
President, Chief Executive Officer, Principal Financial Officer, Treasurer, Company Secretary, DirectorMichael Rowe6322.11.2024
Chief Operating OfficerBren Kern4401.01.202301.01.2023
Chief Investment Officer, DirectorHyunsu Jung2917.06.202517.06.2025